Other languages Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
3.26 ^USD	+4.49%		-4.12%	-55.34%

May. 08	Top Premarket Gainers	MT
May. 08	Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Gainers	May. 08
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE	Apr. 30
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition	Apr. 30
Repare Therapeutics Inc. Announces Directorate Changes	Apr. 26
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	Feb. 15
Repare Therapeutics to Regain Global Rights to Oncology Therapy Camonsertib After Termination of Collaboration With Roche	Feb. 13
Repare Therapeutics Inc. and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer	Jan. 04
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: Rp-1664, an Oral Plk4 Inhibitor, and Rp-3467, an Oral Pol Inhibitor	Nov. 15
Repare Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Repare Therapeutics Reports 'Positive Initial Data' From Trial for Lunresertib	23-10-13
Repare Therapeutics Inc. Reports Positive Initial Data from Modules 1 and 2 of its Ongoing Phase 1 Mythic Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib, an ATR Inhibitor	23-10-13
Repare Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Insider Sell: Repare Therapeutics	23-06-09
Repare Therapeutics Says Lunresertib Showed Antitumor Activity in Phase 1 Trial for Advanced Solid Tumors	23-06-08
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials	23-06-07
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Repare Therapeutics Inc. Announces Board Changes	23-04-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Other languages

Filters